What is Inventisbio?
Inventisbio, formally known as 益方生物科技（上海）股份有限公司, is a China-based pharmaceutical research and development firm with a global outlook. The company is dedicated to developing novel treatments for major diseases, with a particular emphasis on oncology and autoimmune disorders. Inventisbio's robust product pipeline includes two approved drugs and three compounds currently undergoing clinical trials, spanning from Phase I to Phase III. Their research focuses on kinase-driven tumor genes and synthetic lethal pathways, aiming to deliver effective therapeutic solutions. The company's strategic positioning in drug development is further solidified by its consistent access to significant capital, enabling its progression through critical research and clinical phases.
How much funding has Inventisbio raised?
Inventisbio has raised a total of $247M across 4 funding rounds:
Series A
$11M
Series B
$19M
Series C
$70M
Series D
$147M
Series A (2016): $11M with participation from Sinopharm Capital Management
Series B (2017): $19M led by OrbiMed
Series C (2019): $70M supported by Lilly Asia Ventures, CMB International Capital, OrbiMed, Shanghai Pudong Innotek Group, and Advantech Capital
Series D (2020): $147M featuring E Fund Capital, Qiming Venture Partners, Dyee Capital, GL Ventures LLC, Janchor Partners Limited, Matrix Partner China, and AIHC Capital
Key Investors in Inventisbio
Sinopharm Capital Management
Sinopharm Capital Management is a professional private equity firm specializing in the medical and healthcare industry, leveraging the extensive resources of the Sinopharm Group to support innovative companies.
Lilly Asia Ventures
Lilly Asia Ventures is a leading venture capital firm focused on the biomedical sector, dedicated to partnering with entrepreneurs to build companies developing breakthrough products that improve human health.
OrbiMed
OrbiMed is a specialized investment firm with deep expertise in the healthcare sector, managing capital across biopharmaceuticals, medical devices, and digital health platforms, supporting companies at various stages of development.
What's next for Inventisbio?
The recent major strategic investment positions Inventisbio for accelerated expansion and further clinical development. With a strong foundation in tumor metabolism and autoimmune disease research, the company is poised to advance its pipeline, potentially bringing more approved treatments to market. This capital infusion will likely support scaling up manufacturing capabilities, expanding clinical trial operations globally, and potentially exploring new therapeutic areas. Inventisbio's trajectory suggests a continued focus on innovation and strategic partnerships to enhance its market presence and deliver on its mission of providing advanced medical treatments.
See full Inventisbio company page
